EZH2/cMET may serve as biomarkers to stratify chondrosarcoma patients for cMET inhibitor treatment.

Metastases-associated fibroblasts show stage-dependent transcriptional plasticity and their rewiring is regulated by Myc.

The PPARγ protein acts in macrophages to inhibit breast cancer progression and mediate the anti-tumor effects of rosiglitazone by suppressing Gpr132 – a pro-tumor and pro-inflammatory factor in macrophages.

Many extracellular matrix proteins that are up-regulated during breast tumor progression enhance metastasis, and some are prognostic indicators of poor survival.

The MYC transcription factor network member MGA is a subunit of a non-canonical Polycomb complex, which, when inactivated, accelerates tumorigenesis in mouse models of cancer and proliferation in colon organoids.

Assessments using chemogenetic and pharmacological approaches reveal that modulation of the activities of oxytocin neurons in the hypothalamus of the central nervous system could inhibit colorectal cancer progression in mice.

A large-scale single-cell RNA sequencing experiment explores single-cell dynamics in epithelial and immune populations within murine prostates upon cancer initiation and progression and validates key findings across orthogonal models and patient specimens.

Bariatric surgery reversed obesity-exacerbated tumor burden and increased efficacy of anti-PD-L1 immunotherapy.

The retinoblastoma tumor suppressor regulates cell cycle progression when it's in 14 mono-phosphorylated isoforms.